Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
O-acetyl pectin-rEPA conjugate vaccine
- Development stage
- Phase 1
- Lead developer
- National Institute of Child Health and Human Development
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Injection
01
Overview
The O-acetyl pectin-rEPA conjugate vaccine is an investigational semi-synthetic conjugate vaccine developed by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) for the prevention of typhoid fever. The vaccine is designed to mimic the Vi capsular polysaccharide of *Salmonella typhi*, which is the primary target for protective immunity. It consists of O-acetylated pectin (OAcPec), a chemically modified plant polysaccharide derived from citrus peel, which is antigenically modified to resemble the bacterial Vi antigen. This polysaccharide is covalently conjugated to a carrier protein, recombinant exoprotein A from *Pseudomonas aeruginosa* (rEPA), to convert the T-cell independent polysaccharide into a T-cell dependent antigen, thereby enhancing immunogenicity and potentially extending protection to young children and infants. Clinical evaluation in Phase 1 trials has demonstrated that the vaccine is safe and capable of eliciting specific IgG antibodies against the Vi polysaccharide.
- Other names
- O-acetyl pectin-rEPAVi O-acetyl pectin-rEPA conjugate vaccineSalmonella Typhi Vi O-Acetyl Pectin-rEPA Conjugate Vaccine
02
Targets
Vi polysaccharide-specific B-cell receptorVi antigen (Vi capsular polysaccharide)
Beyond the preview
Go deeper on O-acetyl pectin-rEPA conjugate vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on O-acetyl pectin-rEPA conjugate vaccine.